Literature DB >> 15876006

Cost-effectiveness of clopidogrel.

Christopher P Cannon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15876006     DOI： 10.2165/00019053-200422004-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  11 in total

1.  Health and economic benefits of increased beta-blocker use following myocardial infarction.

Authors:  K A Phillips; M G Shlipak; P Coxson; P A Heidenreich; M G Hunink; P A Goldman; L W Williams; M C Weinstein; L Goldman
Journal:  JAMA       Date:  2000-12-06       Impact factor: 56.272

Review 2.  Critical issues in peripheral arterial disease detection and management: a call to action.

Authors:  Jill J F Belch; Eric J Topol; Giancarlo Agnelli; Michel Bertrand; Robert M Califf; Denis L Clement; Mark A Creager; J Donald Easton; James R Gavin; Philip Greenland; Graeme Hankey; Peter Hanrath; Alan T Hirsch; Jürgen Meyer; Sidney C Smith; Frank Sullivan; Michael A Weber
Journal:  Arch Intern Med       Date:  2003-04-28

3.  Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study.

Authors:  Joanne M Murabito; Jane C Evans; Kenneth Nieto; Martin G Larson; Daniel Levy; Peter W f Wilson
Journal:  Am Heart J       Date:  2002-06       Impact factor: 4.749

4.  Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.

Authors:  Sean C Beinart; Paul Kolm; Emir Veledar; Zefeng Zhang; Elizabeth M Mahoney; Olivier Bouin; Sylvie Gabriel; Joseph Jackson; Roland Chen; Jaime Caro; Steven Steinhubl; Eric Topol; William S Weintraub
Journal:  J Am Coll Cardiol       Date:  2005-09-06       Impact factor: 24.094

5.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Authors:  Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Authors:  S R Mehta; S Yusuf; R J Peters; M E Bertrand; B S Lewis; M K Natarajan; K Malmberg; H Rupprecht; F Zhao; S Chrolavicius; I Copland; K A Fox
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

7.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

8.  A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort.

Authors:  A Peeters; A A Mamun; F Willekens; L Bonneux
Journal:  Eur Heart J       Date:  2002-03       Impact factor: 29.983

9.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

10.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).

Authors:  Eugene Braunwald; Elliott M Antman; John W Beasley; Robert M Califf; Melvin D Cheitlin; Judith S Hochman; Robert H Jones; Dean Kereiakes; Joel Kupersmith; Thomas N Levin; Carl J Pepine; John W Schaeffer; Earl E Smith; David E Steward; Pierre Theroux; Raymond J Gibbons; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Sidney C Smith
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.